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Abstract 
Radiotherapy has become one of the most prominent and effective modalities for cancer 
treatment and care. Ionising radiation, delivered either from external or internal sources, 
can be targeted to cancerous cells causing damage to DNA that can induce apoptosis. 
External beam radiotherapy delivers either photon radiation (x-rays or gamma rays) or 
particle radiation (neutrons or protons) in a targeted manner to specific tumour locations. 
Internal radiotherapy involves placing radioactive sources within the body to deliver 
localised doses of therapeutic radiation to tumours using short range radionuclides. 
Biomaterials have been developed to allow more precise targeting of radiotherapy in order 
to reduce toxicity to surrounding healthy tissues and increase treatment efficacy. These 
unique biomaterials have been developed from polymers, glasses and ceramics. Polymeric 
materials have been used to both displace healthy tissue from tumours receiving radiation, 
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and to deliver radioactive sources into the body. These polymers can respond to various 
stimuli, such as radiation or reactive oxygen species, to deliver therapeutic payloads to 
target tissue during or post radiotherapy. Glass-based biomaterials doped with radionuclides 
have also been developed to provide in situ radiotherapy. Novel biomaterials that can 
enhance the synergistic effect of other treatment modalities, such as chemotherapy and 
immunotherapy, continue to be developed. Theranostic materials that are capable of 
providing diagnostic information whilst simultaneously delivering a therapeutic effect to 
enhance radiotherapy are also briefly reviewed. 
Keywords 
Radiation therapy; biomaterials; cancer; brachytherapy; radiotherapy; radionuclides; glass; 
oncology 
 
1. Introduction 
Radiotherapy has become one of the most common and vital modalities for effective cancer 
treatment and care, and is used either alone or in combination with surgery, chemotherapy and 
immunotherapy in approximately half of all cancer cases worldwide [1]. Ionising radiation is 
utilised for the treatment of cancer due to its ability to deposit energy that damages the genetic 
material of cells, resulting in their inability to survive and proliferate further. The unregulated 
manner in which cancer cells rapidly proliferate means that they are more susceptible to 
radiation-induced DNA damage than normal healthy cells [2]. Irradiation can damage the DNA 
double helix structure by inducing DNA single and double-strand breaks, which in turn induces 
cellular events such as apoptosis, necrosis and abnormal mitosis [3]. DNA can also be damaged 
indirectly by reactive oxygen species (ROS) and through free radicals generated in cells by 
radiation (see Figure 1) [4]. The genomic instability of cancer cells means that they are inefficient 
or lack the ability to effectively repair DNA damage induced by radiation in comparison to normal 
cells. This mechanism underpins radiotherapy’s selectivity for inducing cancer cell death [5]. 
Unfortunately, radiation inadvertently causes damage to normal cells adjacent to cancerous cells, 
or those in the radiation path. As such, advancements in this field need to consider maximising the 
dose of radiotherapy to aberrant cancer cells whilst minimising exposure to normal healthy cells.  
The dose of radiation can also directly influence the efficacy of treatment and in clinical settings 
the prescribed dose is usually a compromise between tumour control probability (TCP) and normal 
tissue complication probability (NTCP) [6]. The location of the tumour is the principal factor when 
considering NTCP and can vary throughout the body due to discrepancies in the radiosensitivity of 
different healthy and cancerous tissues. Since NTCP is the primary dose-limiting factor in 
radiotherapy multiple measures and techniques have been used to protect healthy tissue from 
radiation damage [7].  
Depending on the type of cancer, radiotherapy can be used to cure localised cancer, either as 
palliative treatments to reduce symptoms, or to limit progression of the disease in incurable cases 
[8]. Radiotherapy is also often used in conjunction with other treatment modalities such as 
chemotherapy, immunotherapy and surgery. Radiotherapy can be delivered at different stages of 
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a patient’s treatment regime. Neoadjuvant radiotherapy is performed pre-operatively with the 
aim of reducing the size of a tumour prior to surgical resection. Radiotherapy can also be used as 
an adjuvant therapy intra- operatively and post-operatively to help eliminate any residual tumour 
cells [9]. 
 
Figure 1 (a) Schematic of how ionising radiation utilised for radiotherapy can damage 
DNA. Radiation can directly damage DNA or indirectly damage it through the 
generation of reactive oxygen species (ROS). (b) DNA damage can occur as a result of 
single-strand breaks (SSB), double-strand breaks (DSB) or other interactions with DNA 
and proteins. 
The radiation itself can be delivered to cancerous targets in two opposing ways, Externally or 
Internally. External beam radiotherapy is the most prevalent form of radiotherapy used in the 
clinical setting and involves aiming high-energy rays, in the form of photons (X-rays or gamma 
rays), protons or particle radiation, from outside of the body to the specific tumour site. 
Conversely, internal radiotherapy occurs as a result of placing radioactive sources within the body, 
usually adjacent to or directly into the tumour itself [10]. Technological advances are continuing to 
drive progression in both external and internal radiotherapy in order to improve its therapeutic 
efficacy and reduce adverse effects. 
Technological advances in imaging techniques in conjunction with the ability to shape radiation 
beams have resulted in the development of highly conformal external beam radiotherapies (EBRT). 
These techniques can accurately target a tumour site and deliver a maximum ionising radiation 
dose to the target whilst minimising the dose to surrounding healthy tissue [11]. Photon radiation, 
either x-rays produced by accelerating electrons or gamma rays from the decay of radioactive 
substances, are considered low linear energy transfer (LET) electromagnetic rays. Despite their low 
LET, the progression of linear electron accelerators which produce energy-tuneable 
bremsstrahlung x-rays has led to them being the most widespread source for many current EBRT 
regimens [12]. Particle radiation where heavier particles than electrons, in the form of neutrons or 
protons, are targeted to the tumour can also be performed. These particles have higher LET than 
photons and subsequent increased ability to damage cancer cells. The associated costs of 
generating the particles used and delivering particle radiation at treatment facilities has so far 
limited their use [13]. The modality, total dose and fraction of the radiotherapy schedule are 
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considered on an individual basis and are dependent on both the condition of the patient and the 
location of the cancer [14]. 
There are several different types of photon beam radiotherapy used for cancer treatment. 
Three-dimensional conformal radiation therapy (3D-CRT) utilises computed tomography (CT) 
imaging to facilitate accurate determination of the tumour location and position of any potential 
adjacent critical structures. From this information, optimal beam placement from multiple 
directions can precisely match the shape of the tumour and therefore increase its irradiation 
whilst also identifying regions that necessitate shielding [15]. Intensity modulated radiation 
therapy (IMRT) is very similar to 3D-CRT with the advantage of being able to control the strength 
of the individual beamlets to certain regions. The intensity modulation ability of IMRT enables the 
delivery of irregular shaped radiation doses which can conform to the tumour whilst 
simultaneously avoiding critical structures [16]. Stereotactic body radiation therapy (SBRT) 
integrates these technological advances to precisely deliver very high individual doses of radiation 
over very few treatment fractions, to ablate well-defined small tumours. However, SBRT can 
subsequently damage adjacent tissue due to the elevated radiation dose [17]. 
Conformal external beam radiotherapies can allow for dose escalation to target regions whilst 
sparing normal tissue. This can lead to hypofractionated schedules, which involves the delivery of 
fewer, larger doses of radiotherapy in a highly precise manner which can provide radical curative 
effects at local tumour regions [18]. Despite this, clinical considerations such as location of the 
tumour and its subsequent proximity to surrounding critical organs and radiosensitive tissue can 
mean it may not always be possible to utilise EBRT. In such cases, internal radiotherapy becomes a 
viable option.  
2. Internal Radiotherapy  
Radiopharmaceuticals are medicinal products that contain radioisotopes which can be used for 
diagnostic or therapeutic clinical applications [19]. Radioisotopes such as 153Sa, 223Ra, 131I and 89Sr 
can be combined with an excipient for the systemic treatment of certain types of cancer including 
bone, prostate and thyroid cancer (see Table 1) [20]. Radiopharmaceuticals can be administered 
orally or intravenously with the aim of delivering them to accumulate at the desired cancer site. 
Conjugation of a radioisotope to monoclonal antibodies or to peptides that target cancer-
associated cell surface antigens has also been explored in order to deliver a high dose of radiation 
to the tumour in therapeutic approaches known as radioimmunotherapy and peptide receptor 
radionuclide therapy [21, 22].  
Both 223Ra and 89Sr have been used for the treatment of secondary bone cancer, particularly 
when the cancer has metastasised to multiple bone sites, since they are both alkaline earth metals 
and follow very similar metabolic pathways in vivo to calcium [23]. As a result, these 
radiotherapeutic agents localise in bone mineral to act as bone-targeting therapies following 
intravenous injection. The uptake of these agents occurs preferentially at sites of active 
osteogenesis meaning that a greater concentration of these agents can occur at osteoblastic 
lesions and multiple metastatic sites simultaneously [24]. The ionising radiation emitted from 
these radiopharmaceuticals have varying tissue penetration depths and consequently are able to 
target bone metastases with minimal irradiation to adjacent soft tissues (see Table 1). The 
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systemic administration of radiopharmaceuticals is limited to only a small number of 
aforementioned anatomical tumour locations. The majority of cancers require the ablative 
radiation dose to be targeted and to occur directly at the cancerous tissue over a short time 
period, with a rapid fall-off in dose to ensure minimal irradiation of healthy tissues [25]. 
Table 1 Common radiopharmaceuticals used in the systemic delivery of radionuclides. 
Radionuclide Half-life 
(Days) 
Type of 
emission 
Tissue penetration 
depths (mm) 
Type of cancer treated Reference 
89Sr 50.5 β 2.4-8 Bone metastases [20] 
223Ra 11.4 α <0.1 Bone metastases [23] 
131I 8.04 β,γ 0.6-2.4 Differentiated thyroid cancer, 
non-Hodgkin’s lymphoma, 
neuroblastoma 
[26] 
177Lu 6.7 β,γ 1-2.2 Neuroendocrine tumours [27] 
90Y 2.7 β 2.5-11 Neuroendocrine tumours, Liver 
metastases, hepatocellular 
carcinoma, non-Hodgkin’s 
lymphoma  
[28] 
153Sm 1.9 β 0.6-3 Bone metastases [27] 
3. Brachytherapy  
Brachytherapy is a type of internal radiotherapy that involves the placement of sealed 
radioactive sources adjacent to or within the interstitium of cancerous tissue. The location in 
which the radioactive source is placed is used to classify the type of therapy i.e. intracavitary 
brachytherapy, interstitial brachytherapy, intraluminal/intravascular brachytherapy or superficial 
brachytherapy [29]. Brachytherapy can be further classified according to the dose rate applied, 
using the International Commission on Radiation Units stating that 0.4 to 2 Gy.h-1 is a low dose 
rate (LDR); 2 to 12 Gy.h-1 is a medium dose rate (MDR) and a high dose rate (HDR) is regarded as 
being greater than 12 Gy.h-1 [30]. In pulse dose rates, pulses of 1 to 3 Gy.h-1 are used to deliver a 
large number of small fractions with short intervals. HDR brachytherapy typically involves the 
temporary placement of a radioactive source, whilst LDR usually involves permanent implantation. 
The location of the tumour and various patient related factors determine the type of 
brachytherapy conducted. For example, low-energy photon emitting sources, such as 125I and 103Pd, 
have typically been used for LDR whereas high energy emitting 192Ir and 60Co sources have been 
used for HDR [31]. In many instances, brachytherapy facilitates the delivery of a highly localised 
radiation dose that is unable to be achieved using conventional external beam radiation therapy 
[32]. This is because the absorbed dose is inversely proportional to the square of the distance of 
the radioactive source [33]. This means that as you double the distance from the radiation source, 
you reduce the dose by a factor of four as the energy is spread over four times the area. Prostate, 
cervical, oesophageal and certain types of breast cancer are the predominant types that have 
been used for treatment with brachytherapy [34].  
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Advanced imaging modalities, such as magnetic resonance imaging (MRI), computed 
tomography (CT) and ultrasound, have also been used in conjunction with sophisticated treatment 
planning software to determine the precise location in which to place the radioactive sources [35]. 
Correct placement of these sources enables the optimal dose distribution at the target site to be 
achieved on a patient specific basis. This allows for the delivery of conformal radiotherapy tailored 
to the size and shape of the individual tumour (see Figure 2) [25]. 
 
Figure 2 Schematic of prostate brachytherapy delivery. Radioactive seeds are 
implanted into the prostate using trans-rectal ultrasound (TRUS) guiding and a grid 
template. TRUS is performed to identify the location of seeds deposited within the 
prostate and dosimetric plan is generated. Reproduced with permission from [36] 
(Cancer Research UK/ Wikimedia Commons). 
Brachytherapy is an invasive technique as it requires surgical insertion to deliver radioactive 
sources to specific cancer sites. In permanent brachytherapy, the radioactive source is sealed 
within a protective capsule to create a brachytherapy seed ready for implantation (see Figure 2). 
Titanium is the most common material used for conventional seeds as it provides structural 
integrity to the seed so that it remains in situ whilst also preventing the escape of the radioactive 
source [37]. The use of titanium also allows for MRI-guided insertion enabling improved accuracy 
of placement, which can be performed by remotely controlled afterloading devices, removing the 
need for manual handling and insertion of radioactive sources. Automation of this procedure can 
improve the accuracy of the therapy alongside significantly reducing radiation exposure to 
clinicians [38]. New seed and applicator devices continue to be developed along with alternative 
materials to address different clinical aspects associated with cancers at various body sites [39]. 
Improvements in applicator and seed design and geometry will allow for better visualisation from 
the various imaging modalities used, resulting in more accurate implantation and retention, which 
in turn will translate to more accurate and effective dosimetry at the target site. Custom 
applicators and seed devices are also desirable when conventional devices fail to conform or adapt 
to patient specific anatomy [40]. 
One novel brachytherapy implant device that has been developed is CivaSheet® (CivaTech, 
Durham, NC). Unlike traditional seed implants, CivaSheet is comprised of a flexible, planar 
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bioabsorbable membrane which contains multiple unidirectional radioactive sources, known as 
CivaDots, fixed within its proprietary polymer matrix at regular intervals (see Figure 3) [41]. The 
103Pd radiation source is placed on top of a thin gold shield which imparts directional radiation that 
can selectively target cancerous tissue whilst sparing healthy tissue on the shielded side. The gold 
disc serves to shield the radiation and as a radiopaque marker that can be visualised using CT 
imaging [42]. The device also enables clinicians to utilise custom sizes of the device and the 
malleable nature of its planar membrane means it can conform to various physiological structures 
depending on the location of tumour and the patients’ anatomy. This device can be applied 
intraoperatively during tumour resection and can also be administered via less invasive methods 
during a treatment regimens [43]. As within any brachytherapy device, the dosimetric 
characteristics of the source must be established and requires numerous in silico, in vitro and in 
vivo studies to ascertain the feasibility of new devices [44]. 
 
Figure 3 (a) Schematic of the cross-section of a CivaDot and its composition. (b) 
Illustration of a CivaSheet brachytherapy device. The CivaDots are orientated within 
the bioabsorbable membrane to provide unidirectional radiation. Adapted with 
permission from ©  Wiley [45]. 
One issue with permanent brachytherapy seeds, is that in certain instances they can require 
surgical removal. Sano et al. investigated the use of biocompatible, injectable thermos-responsive 
polymer labelled with 90Y [46]. Poly (2-alkyl-2-oxazoline) (POZ) is an isomeric polypeptide material 
synthesised via the cationic ring-opening polymerisation of 2-oxazolines [47]. Modifications of the 
2-substituent of the 2-oxazoline monomer allowed for modifications to the POZ polymer 
sidechains. POZ derivatives have a low critical solution temperature (LCST), and can self-aggregate 
above a specific transition temperature (Tt) that is determined by oxazoline composition and 
molecular weight of its polymers [48]. Sano et al. utilised the thermo-responsive characteristic of 
POZ derivatives to create polymers that were soluble at room temperature and upon intratumoral 
injection, rapidly self-aggregated into rigid structures retained within the tumour. The enhanced 
permeability and retention effect demonstrated to cause POZ accumulation within tumours and 
the ability to label a radioactive source to the polymer facilitated their potential use as injectable 
materials for brachytherapy (see Figure 4) [49]. 
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Figure 4 Concept of injectable, thermo-responsive, radioisotope labelled polymers that 
aggregate within tumours for brachytherapy applications. This research was originally 
published in JNM ©  SNMMI [46].  
Rhenium loaded silicate-based glass seeds is another material that has been investigated for 
brachytherapy administration. Utilising the sol-gel processing method it was possible to 
incorporate stoichiometric amounts of rhenium within silicate-based glasses (with formulation 20% 
rhenium, 50% silicon and 30% calcium, neither weight nor mole % was provided) and fabricate 
seeds of a predetermined geometry [50]. 186Re has a relatively short half-life of 16.9 hours and 
offers the possibility of releasing high energy β-emission over a short time period in comparison to 
other radionuclides with longer half-lives [51]. Knowing the geometry of the seed, the energy 
generated per seed and the dosimetric factors of the source, it was possible to calculate the 
number and location of seeds required to be placed in order to deliver effective brachytherapy to 
a tumour. Several rhenium based radiotherapy treatments are currently in early phases of clinical 
trials investigating the utility of 186Re and 188Re isotopes [52]. 186Re has a lower β-emission than 
188Re with a maximum tissue penetration of 4.5 mm and a half-life of 3.6 days, making 186Re an 
ideal candidate for treating small to mid-sized tumours. The larger tissue penetration depth of 
188Re, maximum of 11 mm, and its shorter half-life means that it could be employed for the 
treatment of larger tumours over a short time period [51]. Radiotherapy from 188Re sources has 
been investigated for medullary carcinomas of the head and neck [53], hepatocellular carcinomas 
[54] and for brachytherapy of basal or squamous cell carcinomas [55].  
An alternative device to typical brachytherapy seeds was the use of conical-shaped needles, 
similar to those used in microneedle arrays for transdermal drug delivery, to penetrate into solid 
tumours to deliver intratumoral doses of radiation. Kim et al. investigated using titanium (Ti) and 
molybdenum (Mo) needles coated using pulsed laser deposition or chemical vapour deposition 
with holmium (Ho) or rhenium (Re) that following neutron activation readily yield therapeutic 
radionuclides [56]. 166Ho is produced following irradiation of 165Ho in a neutron flux and decays to 
emit high energy, tumoricidal β-particles. 186Re and 188Re are also both β-emitters and like 166Ho 
also emit photons (x-rays and γ-rays) which can be detected using Single Photon Emission 
Computer Tomography (SPECT) facilitating their use as theranostic agents [57]. Pulsed laser 
depositions was used to ablate Ho foil within a vacuum using an intense pulsed laser causing the 
formation of a Ho plasma plume that condensed on to Ti needles. Ti was chosen as the needle 
material due to its high biocompatibility and strength as well as the ease at which needles of 
specific sizes and geometries can be fabricated. Importantly, Ti produces a very low amount of 
radioactive isotopes, following neutron activation, that are deemed negligible and unable to cause 
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significant cellular damage, further validating the choice of material [58]. Despite the ability to 
control the amount of Ho coated onto Ti needles and therefore tailor the amount of radioactivity, 
Ho deposition was found to dissociate from the needle when in acidic conditions that mimicked 
the intracellular environment of solid tumours. In the same study, Re of varying thickness (25, 75 
and 125 µM) was uniformly deposited on Mo needles by chemical vapor deposition. This process 
involved passing a rhenium pentachloride containing precursor vapour over a heated Mo needle. 
Stability studies demonstrated only minimal leaching of radioactive Re was observed in neutral 
and acidic (pH 3.5) environments. Unlike Ti, following neutron irradiation Mo produces 
undesirable radionuclides and daughter isotopes that would have to be considered when 
calculating radiation dosimetry for patients. In order to prevent the generation of such 
radionuclides, a gadolinium (Gd) shield was created that housed the base of the device to absorb 
neutrons. The very high neutron cross-section of Gd prevents the Mo base from neutron 
activation, whilst allowing the protruding Re-coated Mo needle to become radioactive [59]. These 
neutron-activated biomaterials offer the possible to provide personalised internal radiotherapy 
treatment by optimisation of the needle material, geometry and quantity, the thickness of 
radionuclide coating as well as the radionuclides used based upon the size and location of the 
tumour to be treated. The advantageous nuclear properties of Ho and Re, such as their high 
neutron capture cross-sections, half-lives and resultant radionuclides upon decay make them 
attractive elements to form theranostic devices.  
4. Polymeric Biomaterials, Applicators and Spacers  
The benefits of radiotherapy when combined with the surgical resection of breast tumours for 
example, has been validated in multiple clinical studies and is considered a preferential breast 
conservation therapy in early stage breast cancer [60]. Accelerated partial breast irradiation (APBI) 
involves radiotherapy targeted directly to the lumpectomy bed and a 1-2 cm margin as opposed to 
radiotherapy delivered to the entire breast [61]. This process spares adjacent healthy tissue and 
enables a higher dose of radiation to be delivered to the target in a shorter treatment period. 
Combination therapy has been shown to decrease local recurrence of cancer as well as improve 
overall survival rates in patients with early-stage breast cancer [62]. Several different approaches 
have been employed to deliver the radiotherapy including intra operative radiation therapy and 
conformal EBRT although multicatheter interstitial brachytherapy and balloon catheter 
brachytherapy are most commonly used [63]. For these procedures and other types of temporary 
brachytherapy, catheters are used to place radioactive sources within an applicator into a 
predetermined location for a set period of time. 
The development of flexible polymer-based catheters and applicators that are able to 
accurately place, using image-guided techniques and afterloading equipment, to retain radioactive 
sources in the correct location and orientation have been central to the progression of therapies 
such as APBI [64]. Numerous polymers such as silicone, nylon, polyurethane, polyethylene 
terephthalate (PET) and thermoplastic elastomers are utilised for the generation of commercially 
available and custom catheters. The combination of polymeric components provides desirable 
characteristics and can be manufactured and tailored for specific applications [65]. Polymer based 
devices that have multiple regions where a radioactive source can be accurately placed that derive 
from a single entry device are now common practise within the clinic [66]. Devices such as the 
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Strut Adjusted Volume Implant [67] device (Cianna Medical, California) comprises of a central strut 
encircled by either 6, 8 or 10 peripheral struts and ClearPath (North American Scientific, California), 
where inner and outer catheters can be independently expanded to give varying expansion radii, 
are becoming more prevalent due to their enhanced ability to conform to the lumpectomy cavity 
during APBI [68, 69]. The combination of radio-opaque markers located within the peripheral 
struts and the ability to differentially load the struts with high-dose radiation sources facilitate 
accurate treatment processes [70]. The catheters are inserted at predetermined distances 
between them to ensure sufficient coverage of the lumpectomy region plus an acceptable margin 
[64]. 
Balloon catheter brachytherapy is routinely used in APBI and are similar in respect to 
multicatheter devices in that they are single entry devices that are expanded to provide 
conformance of the lumpectomy cavity to the balloon. The MammoSite® (Hologic, Massachusetts) 
and the Contura balloon device (SenoRX, California) are FDA approved brachytherapy devices and 
consists of a silicone balloon connected to a dual-lumen catheter which controls the inflation and 
delivery of the radioactive source [71, 72]. A saline solution containing control material is used to 
inflate the balloon to the desired diameter and 192Ir can be remotely after-loaded into the device 
at the prescribed radiation dose. The diameter of the inflated balloon, the distance of the balloon 
to the skin and the dose distribution are all interrelated factors that must be considered in order 
for effective treatment using this method [73]. Axxent electron brachytherapy system (Xoft, 
California) is another balloon-based applicator that differs slightly in that an electronic 50 kilo-
voltage x-ray source is used to deliver radiation as opposed to 192Ir. Since an x-ray tube is used 
within the balloon catheter this process eliminates the need for a high dose rate afterloader and 
the use of a shielded vault meaning that this procedure may be more accessible for some patients 
[74]. 
Researchers continue to develop novel balloon applicator designs that are able to increase the 
therapeutic effect they have whilst in situ [75]. Balloon applicators designed using alternative 
biomaterials at their interface have been investigated for localised delivery of therapeutic 
payloads. The added treatment intervention can be seamlessly integrated into conventional 
treatment practise as they do not compromise the primary function of the balloon applicators or 
require additional interventional procedures. Ouyang et al. investigated coating balloon 
applicators with a degradable polymer film that could release cerium oxide nanoparticles (CONPs) 
to act as radical scavengers during APBI (Figure 5) [76]. An inherent feature of radiotherapy is its 
inability to discriminate between healthy and cancerous tissue which leads to unwanted adverse 
effects. The radiation-induced generation of reactive oxygen species (ROS), such as hydroxyl 
radicals (OH·) and hydrogen peroxide (H2O2), can cause unrepairable DNA damage to healthy and 
cancerous cells [77]. CONPs have been have shown to be capable of the catalytic removal of ROS 
and thereby could help to protect normal cells from ROS-induced apoptosis [78]. The selective 
protection is driven by the pH dependence of the CONP induced catalysis and normal cells have a 
neutral intracellular environment whereas cancerous cells tend to be acidic [79]. Ouyang et al. 
proposed that CONPs could diffuse from polymer films as they degrade within the body and 
accumulate in the surrounding tissue of the lumpectomy cavity. The rate of diffusion into the 
tissue could be tailored by the concentration of CONPs and the degradation rate of the polymer 
film so that the radioprotective effect could be matched to the radiation schedule to increase the 
effectiveness of treatment [76].  
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Figure 5 Schematic of a potential balloon applicator that is coated with a polymer film 
loaded with cerium oxide nanoparticles for radioprotection of healthy tissue during 
accelerated partial breast irradiation.  
One method used in brachytherapy, as well as in EBRT, to achieve maximal tumour radiation 
dose whilst limiting the exposure of surrounding healthy tissue is the incorporation of 
radioprotective spacers. Spacers are surgically positioned into predetermined locations and 
manually displace healthy tissues and adjacent organs from the tumour. When the radiation 
source is active at the tumour site, healthy tissues are pushed further away and therefore receives 
a lower absorbed dose [80]. This helps to alleviate damage to healthy tissue and reduce radiation-
induced adverse events. Spacers are predominantly, although not exclusively, used in cancers of 
the abdominal and pelvic regions and are widespread in the treatment of cervical and prostate 
cancer due to the relative ease of implantation [81]. The size, shape and material used for 
radiotherapy spacers is dependent on the anatomical site of the tumour. Natural materials such as 
human collagen [82] and hyaluronic acid [83] have been investigated as spacers due to their 
biocompatibility and biodegradability. Although the preliminary clinical indications on the use of 
hyaluronic acid and human collagen were encouraging, hyaluronic acid was found to be unstable 
when exposed to radiation and highly viscous making accurate injection a technical challenge, 
whereas the availability of human collagen has limited its utilisation [84]. Polyethylene-glycol (PEG) 
hydrogel is a non-toxic, non-immunogenic and bioresorbable material and is commonly employed 
as a radioprotective spacer for use in prostate cancer treatment [85]. SpaceOAR™ (Augmenix Inc., 
Waltham, MA) is currently the only FDA approved hydrogel for use in prostate cancer radiation 
therapy [86]. The hydrogel is placed between the rectum and the prostate, thereby controlling the 
spatial distribution and accuracy of radiation from brachytherapy seeds within the prostate, whilst 
decreasing rectal damage during radiotherapy (see Figure 6). Spacers can be used in 
brachytherapy as well as being utilised in EBRT, in particular in conjunction with stereotactic body 
radiotherapy (SBRT), where the large fraction sizes used suggest that there is a greater need to 
protect adjacent healthy tissue from damage [87]. In similar studies, PEG hydrogel micro particles 
containing covalently bound iodine have been investigated as radiopaque fiducial markers and 
spacers for gynecologic and pancreatic cancer treatment [80, 88]. The presence of iodine enables 
it to be visible using CT, cone beam computer topography and mammography whilst the high 
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water content of the hydrogel makes it visible via MRI and ultrasound. It has therefore been 
proposed that hydrogels such as this could be accurately placed in regions between the head of 
the pancreas and the radiosensitive duodenum to allow dose escalations of radiotherapy in cases 
of unresectable pancreatic cancer [80]. 
 
Figure 6 Axial T2 MRI images of a patient (a) prior to hydrogel spacer injection, (b) post 
implantation. Reproduced with permission from [89]. 
Domb et al. developed biodegradable balloons as alternative devices capable of acting as 
spacers that can displace the irradiated prostate away from the surrounding tissues, such as the 
rectal wall, in patients undergoing radiotherapy for prostate carcinoma. Biodegradable PLCL 
polymers are used to fabricate the biodegradable balloons (bio-balloons) which can be inserted via 
a minimally invasive procedure through the perineum in a deflated, rolled up conformation before 
being inflated in situ to form a structure with a defined size and volume [90]. The bio-balloons 
were designed to remain inflated and to retain their structural integrity over a period that exceeds 
the radiotherapy treatment, typically around 6 weeks, but fully degrade in the body within a year 
with no residual parts of the device remaining in situ. Both the polymer of choice and the 
methodology used to fabricate the balloon were vital in creating the device with the desired 
physical and mechanical properties. The balloons needed to be formed from a highly homogenous, 
flexible and elastic material that maintains its mechanical properties whilst folded prior to inflation 
and also whilst inflated in vivo. Poly-l-lactide-co- ε-caprolactone (PLCL) was the polymer used since 
this had the necessary mechanical properties and had an optimum degradation profile that was 
shorter than other polyhydroxyacid based biomaterials, such as polycaprolactone (PCL) [91]. The 
bio-balloons were fabricated using a dip coating technique in order for the balloons to be formed 
from a continuous single unit that minimised the number of connecting parts and regions where 
parts were joined/glued. Regions such as these are susceptible to deformation and leakages that 
could cause premature deflation of the bio-balloons in situ. An agarose mould of the desired size 
and shape of the bio-balloon and its nozzle was first formed and subsequently dipped into a 
polymer solution containing 14% w/v of PLCL in the organic solvent dichloromethane. This was 
performed under a dry nitrogen atmosphere to prevent condensation forming on the PLCL layer 
whilst the solvent evaporated. The agarose mould underwent three successive cycles of dipping 
and drying to fabricate balloons with an optimal and homogenous wall thickness of ~100 µm. 
Following completion of the dip coating, the agar mould is removed by dissolving in distilled water 
at 90°C and squeezed out of the balloon nozzle [92]. The balloon is then sterilised using ethylene 
oxide, in order to retain its chemical and mechanical stability, and can be implanted into the 
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desired region in vivo, inflated using physiological saline and sealed using a PLCL plug to displace 
the irradiated prostate from surrounding healthy tissue. Clinical trials have demonstrated the 
safety of the bio-balloons and their ability to increase the rectal-prostate interspace from 0.22 ± 
0.2 cm to 2.47 ± 0.47cm throughout the duration of radiotherapy [93]. The separation decreased 
the radiation exposure to the rectum, thereby reducing the adverse events and facilitating dose 
escalation of the radiotherapy to improve treatment efficacy.  
Endorectal balloons made from silicon or latex have also been routinely employed to physically 
move the dose-limiting structure of the rectum during prostate cancer radiotherapy and to reduce 
prostate motion during treatment [94]. Endorectal balloons have the potential to change the dose 
exposure of surrounding healthy tissue but can increase exposure to the anterior rectal wall 
meaning accurate and controlled placement is vital [95]. Parsai et al. developed a novel, 
detractable device to temporarily displace the rectum to prevent damage during treatment of 
tumours in the pelvic cavity [96]. A Nitinol shape memory wire was placed inside a clinical 
approved endorectal balloon that could be activated by joule heating and controlled through an 
electrical conductor that produces thermal energy as current passes through it. The Nitinol wire 
functions as an actuator that allows the shape of the device to be tailored in situ to accurately 
move the organs adjacent to the body cavity in specific directions. Nitinol is a nickel-titanium alloy 
that is biocompatible and commonly used for medicinal and orthopaedic applications and displays 
biomimetic actuation due to a reversible crystalline phase transformation. Nitinols unique 
reversible shape memory property is due to its two crystalline structures: martensite and 
austenite [97]. Prior to insertions of the endorectal balloon device, Nitinol is soft and flexible due 
to its martensite phase. Once inserted, barium is injected to allow proper localisation of the 
balloon where it can then be inflated and orientated into the correct position. Nitinol is than 
actuated via joule heating causing the transformation of the Nitinol to its austenitic phases, 
thereby causing the Nitinol wire to change its shape. This results in the controlled movement of 
the balloon device that displaces the posterior rectum wall and a subsequent movement of the 
anterior rectum wall away from the proposed radiation field. Following the completion of HDR 
brachytherapy or EBRT, a reduction in temperature causes the Nitinol to return to its original 
martensitic phase and shape so that the device can be deflated and removed from the patient 
with minimal discomfort. Devices such as this have the potential to alleviate morbidities to the 
rectum and facilitate the delivery of escalated, ablative dose of radiation to tumours. 
Currently, the majority of image-guided brachytherapy procedures routinely use inert 
radiotherapy biomaterials for devices such as spacers, seeds and their applicators. The sole 
purpose of these inert biomaterials is to ensure geometric accuracy for the duration of therapy in 
order for a predictable and calculated dose of radiation to be achieved at the cancerous site. 
Recent studies have investigated developing a new generation of radiotherapy biomaterials that 
are multifunctional and capable of enhancing current treatment and delivering additional 
therapeutic effects [98]. These ‘smart’ biomaterials are being designed to be responsive to specific 
stimuli, such as temperature or pH, and responding directly to cancer induced changes due to the 
conditions of the tumour micro-environment. Innovative smart biomaterials can have an active 
response or change in structure thereby facilitating additional functions that could enhance 
treatment, such as targeted drug delivery or initiation of an immune response [99]. 
Although spacers have become critical components for accurate radiation delivery, they 
provide no direct therapeutic benefit. The close proximity of the spacer to the tumour site has 
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driven the rationale that this may also be harnessed for in situ delivery of therapeutic payloads to 
the cancer cells. Kumar et al. [100] developed Implantable Nanoplatforms for Chemo-Radiation 
Therapy (INCeRT) spacers formed using PLGA polymer matrix containing silica nanoparticles (with 
a size of 254 ± 5 nm) embedded within. These spacers were biocompatible with the same 
dimensions as clinically used spacers. The nanoparticles acted as drug/fluorophore depots that 
were released from the PLGA matrix due to its dissolution within the body. The nanoparticles then 
released encapsulated cargo upon interaction with biological fluid enabling the local delivery of 
therapeutics in a controlled and sustained manner. Nanoparticles have the added ability to 
passively target cancerous tissue and accumulate within tumours for an extensive time period due 
to the enhanced permeability and retention (EPR) effect [101]. Nanoparticles, such as those used 
on the INCeRT spacers, that can encapsulate both therapeutic and diagnostic payloads can allow 
for the qualitative assessment and extent of drug distribution within the tumour. Such methods 
could allow for a targeted, high dose of drug to be delivered with greater spatial distribution 
within the tumour. A delivery system like this could offer benefits over many typical 
chemotherapy regimens where systemic toxicities prevent their use throughout the duration of 
radiotherapy. The synergistic effect of radiation and chemotherapy could also be enhanced if 
effective radiosensitisation of the target tissue could be achieved whilst simultaneously sparing 
the neighbouring healthy tissue [102].  
Polymers are attractive materials for sustained use or controlled release of therapeutic 
payloads due to multiple parameters that can be altered to create an optimal release profile. The 
molecular weight and the specific polymer used as well as type, concentration and size of payload 
can be tailored to customise the loading and release rates [103]. Synchronising the 
radiosensitisation or radioprotective effects of the payload with the radiation dosage could 
produce superior therapeutic efficacy [100]. Materials that facilitate this and increase the 
biodistribution of the payload to the target allow for optimisation of individual radiotherapy 
schedules and are therefore hugely desirable [104]. Many radiosensitising and radioprotective 
agents suffer from poor bioavailablity and rapid metabolism, along with having high systemic 
toxicity and therefore must be delivered in a controlled and targeted manner.  
Utilising biomaterials for radiotherapy to deliver nanoparticles that either achieve 
radiosensitisation of surrounding tissue producing a radiation boost or those that can act as 
radioprotectants continues to be an area of intense research [105]. Nanoparticles can be 
fabricated to contain various different payloads and numerous techniques have been explored to 
incorporate them into and within existing biomaterials. Despite this, issues still remain regarding 
the use and delivery of sufficient concentrations of nanoparticles to the tumour site or 
surrounding tissue if this is the intended target. Nanoparticles that do not reach their target site 
could end up in systemic circulation, resulting in off-target effects that could be detrimental to the 
patients’ health [106].  
5. Glass Biomaterials and Selective Internal Radiation Therapy 
Bioactive glasses differ from non-bioactive glasses as they are able to form a continuous 
interface with host tissue upon implantation in the body without triggering fibrosis. This 
phenomenon has led to extensive investigations into their use for a range of potential therapeutic 
applications. The ability to tailor the glass properties by altering the composition of the glass with 
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network modifiers and modifying oxides has been fundamental to these studies [107]. Alterations 
in the glass formulation affect the glasses physico-chemical and mechanical properties, bioactivity 
and dissolution rate. Novel glass formulations have been developed to improve the properties and 
to enhance the clinical translatability of bioactive glasses in order for them to address specific 
medical needs and elicit therapeutic responses [108].  
The versatility of bioactive glasses have led to them being investigated for use in radiotherapy 
since various radionuclides that emit alpha, beta or gamma radiation can be chemically 
incorporated into their structure. Beta-emitting radionuclides have been most extensively studied 
due to their ability to deliver tumoricidal doses of radiation with sufficient levels of tissue 
penetration [109]. The properties of the radionuclide can be used to identify the best candidate to 
deliver the desired dose of radiation, over the appropriate distance, to achieve effective treatment 
of a specific organ or tissue [110]. During the manufacturing and processing procedure, the non-
radioactive radionuclide is incorporated into the chemical and physical structure of the glass. 
Various processing techniques can be used to fabricate bioactive glasses into an array of different 
practical morphologies [107]. The ability to tailor the size and shape of bioactive glass 
microspheres facilitates their transport and delivery to specific locations to provide in situ 
radiotherapy. These glass microspheres are irradiated (i.e. made radioactive) by neutron 
activation of the radionuclides. Since neutron activation is the last step of the manufacturing 
process this provides an inherent safety benefit during glass fabrication. The time from activation 
to when they are actually delivered to clinic for administration can also be used to ensure the 
radiation dose required is provided to the patient. 
Selective internal radiation therapy (SIRT) (also known as radioembolisation) is one method 
that has been employed to treat unresectable hepatocellular carcinoma to great effect. The 
proximity of the liver to adjacent critical organs can prevent the use of conventional EBRT [111]. 
SIRT is a form of internal radiotherapy that involves the delivery of radioactive microspheres to 
selectively irradiate tumours within the liver. The radioactive microspheres are administered via 
the hepatic arteries due to the fact that normal liver cells are predominantly vascularised by portal 
venous flow whereas cancer cells almost exclusively receive arterial blood. The liver 
vascularisation therefore results in the preferential deposition of these microspheres within 
hepatic tumours due to their increased vascularity (see Figure 7) [112]. Following administration, 
the microspheres migrate to and become trapped in hepatic vasculature supplying the tumour. 
The proximity of the microspheres to the tumour results in localised delivery of lethal doses of 
radiation to the tumour whilst sparing healthy parenchyma [113]. The microspheres can 
simultaneously cause a degree of embolisation by occluding the blood vessels to prevent blood 
and nutrient flow to the tumour [114]. There are currently two commercially available, FDA 
approved 90Y containing products used for SIRT [115]. TheraSphere (BTG International, London, 
United Kingdom) are alumina silicate glass microspheres, whereas SIR-Spheres (Sirtex Medical, 
Sydney, Australia) are resin-based microspheres. 90Y is used as it is a pure β-emitter with a tissue 
penetration depth ranging from 2.5-11 mm, capable of delivering therapeutic doses of ionising 
radiation. Despite the differences in physico-mechanical properties between the two different 
materials, both types of microspheres have exhibited comparable efficacy in clinical trials [116]. 
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The 90Y containing resin-based SIR-spheres were developed in the late 1980s and approved by 
U.S. Food and Drug Administration in 2002 for the treatment of hepatic metastases secondary to 
colorectal adenocarcinoma [117]. SIR-spheres are comprised of a proprietary biocompatible 
microsphere that is coated with a cross-linked cation exchange polystyrene resin. 89Y is integrated 
into and immobilised within the resin matrix via ion exchange of sodium for yttrium followed by its 
precipitation as a phosphate salt. This prevents 90Y leaching out of the microspheres, following 
neutron activation, to a level that would be deemed to be physiological important in vivo [118].  
 
Figure 7 Schematic of SIRT and the use of radioactive microspheres for the treatment 
of liver cancer. Microspheres are administered via a catheter into the hepatic 
vasculature. Microspheres emit beta radiation to the tumour cells whilst having an 
embolic effect to further induce tumour apoptosis. Reproduced with permission from 
[119]. 
Traditional melt-quenching technique involving 89Y, aluminium oxide and silicon dioxide is used, 
followed by flame-spheroidisation for Therasphere glass microsphere manufacture [115]. The 
yttrium alumina silicate glass microspheres are composed of 17.1 mol% Y2O3, 18.9 mol% Al2O3 and 
64.0 mol% SiO2 and range from 20-30 µm in diameter (see Table 2). The microspheres are non-
toxic, non-biodegradable and chemically resistant to body fluids [120]. These glass microspheres 
undergo neutron bombardment which causes 89Y to be transduced into the β-emitter 90Y whilst 
the other elements within the glass remain non-radioactive. The 90Y-doped aluminosilicate glass 
microspheres demonstrate high chemical durability, which is essential for neutron activation and 
prevention of 90Y leakage [121]. Since the yttrium is incorporated in the glass structure and not a 
surface coating, it can only leach out of the glass and the target organ if the microspheres degrade 
in vivo during the time its radioactive [122]. The half-life of 90Y isotope is 2.7 days meaning that the 
radioactivity of the microspheres declines to a negligible level within 21 days from initial neutron 
bombardment [123].  
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Table 2 Characteristics of commercially available 90Y containing microspheres used in 
Selective Internal Radiation Therapy. Adapted from [124]. 
Feature SIR-Spheres TheraSpheres 
Isotope 90Y 90Y 
Half-life (hr) 64.2 64.2 
Material Resin Glass 
Diameter (µm) 20-60 20-30 
Activity per particle (Bq) 50 2500 
Spheres per 3 GBq 40-80×106 1.2×106 
Specific gravity (g/mL) 1.6 3.2 
Embolic effect Mild Negligible 
Contrast injection During infusion No 
FDA approved indication CRC liver metastases with intrahepatic floxuridine HCC 
*FDA=Food and Drug Administration; CRC: Colorectal cancer; HCC: Hepatocellular carcinoma. 
Phosphate-based glass microspheres have also been investigated for radiotherapy applications. 
The use of phosphate based glasses is advantageous due to their relatively low melting point to 
allow ease of manufacture and post processing techniques into different practical morphologies. 
Alteration to the composition of phosphate glasses have been shown to control their degradation 
rate over several orders of magnitude, ranging from minutes, days, months to years [125]. This 
makes them attractive resorbable materials to be implanted into the body that can be tailored to 
degrade in vivo at a rate that is optimum for a specific clinical application. Non-degradability is the 
main disadvantage of currently available silicate glass microspheres for SIRT as the glass 
microspheres would remain in the body as an impurity in the target area after radioactive decay of 
90Y [126]. 
31P can also be neutron activated into the β-emitter 32P, which has a half-life 14.3 days [126]. 
32P could potentially provide localised radiotherapy and enable the possibility of being 
incorporated into the glass structure of the microspheres simultaneously with another 
radionuclide such as 90Y. Masakazu et al. studied the effect of phosphorous ion implantation into a 
number of yttrium containing silica glasses to examine the possibility of enhancing their 
radiotherapeutic effect due to the longer half-life of 32P. Whilst high chemical durability was 
obtained, phosphorous can be a problem for some silicate glasses as it plays an integral role in 
nucleation of crystalline phases [127]. Sene et al. investigated the effect of phosphate glass 
microspheres (P2O5-Al2O3-SiO2-MgO) for radiotherapy application and found that the glass 
composition 42P2O5-12Al2O3-4SiO2-44MgO (in weight%) showed the best chemical durability and 
resistance to crystallisation, displaying the feasibility of using phosphate-based glass microspheres 
for radiotherapy applications [128]. The high durability of ceramic yttrium phosphate 
microspheres, composed of Y2O3 and YPO4, have also been explored as potential materials capable 
of delivering radiotherapy [126]. Glass microspheres made from alumina borate glass doped with 
rhenium have also been considered for in vivo radioembolisation therapy since rhenium is 
composed of two isotopes (185Re and 187Re) that can be converted to beta-emitting 186Re and 188Re 
radioisotope respectively, after neutron bombardment (see Table 3) [129].  
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Prior to microsphere administration during SIRT, a diagnostic angiography is conducted to 
assess the vasculature of the liver and tumour. Technetium-99m macroaggregated albumin (99mTc-
MAA) particles, that are comparable in size to the 90Y microspheres, are injected as a scout dose 
and their distribution within the liver studied. Due to 99mTc emitting readily detectable gamma 
rays, single-photon emission CT (SPECT) can be used to estimate the dose to the tumour and 
surrounding parenchyma and to evaluate the potential of pulmonary and extrahepatic shunting 
[130]. Although 99mTc-MAA SPECT dosimetry is accurate for SIRT, alternate methods are being 
developed that can combine the therapeutic radiotherapy with the ability to simultaneously 
achieve diagnostic information at the tumour site. This theranostics based approach could provide 
real time information on the biodistribution of radiotherapeutic agents within a tumour, help 
determine the optimal dose and monitor the response to treatment [131]. 
Barros Filho et al. explored the use of holmium doped phosphate-based glass microspheres as 
alternative materials for SIRT that could also provide theranostic potential [132]. Traditional melt-
quenching method was used to prepare these glasses followed by flame spheroidisation or 
gravitational falling within a furnace was performed to obtain microspheres of the desired 
geometry (see Table 3). Neutron activated 166Ho is comparable to 90Y in that it is a β-emitter, with 
a mean tissue penetration of around 2.5 mm, although it has a significantly reduced half-life of 
26.8 hours [133]. The advantage of using 166Ho is that it is also a gamma emitter, meaning that it 
can be detected using SPECT, as well as its paramagnetic properties allowing for Magnetic 
Resonance Imaging [35, 134]. These clinical imaging techniques could facilitate the real time 
visualisation of the holmium-doped microspheres during and post-treatment and can be used to 
quantitatively measure 166Ho distribution in vivo [133, 135]. 
Radioactive 166Ho loaded poly(L-lactic acid) (PLLA) microspheres (166Ho-PLLA) (QuiremSpheres®, 
Quirem Medical B.V., The Netherlands) have been developed as an alternative to glass 
microspheres for SIRT [136, 137]. The use of 166Ho-PLLA has the potential to eliminate the need of 
a scout dose, such 99mTc-MAA, followed by a therapeutic dose since the 166Ho-PLLA microspheres 
are capable of performing both roles concurrently. The diagnostic feature of 166Ho-PLLA could 
enable monitoring of intrahepatic behaviour of the microspheres during and post treatment [138]. 
Knowledge of the amount of microspheres that reach the cancerous and normal liver tissue of 
each patient allows clinicians to adjust the treatment plan accordingly and identify tumours that 
may be receiving an inadequate dose [139]. Poly(lactic acid) microspheres that contain 30 weight% 
rhenium for liver cancer treatment have also been investigated. Polymers susceptibility to 
degradation due to the use of high neutron fluxes during neutron activation and the difficulty in 
achieving a high enough activity to produce a therapeutic effect must be circumvented when 
developing microspheres for SIRT [140].  
Currently, research has predominantly focused on glasses containing only a single radioactive 
element that can be used to deliver in situ radiation to cancerous tissue. It is feasible that glasses 
could be prepared containing multiple elements that can become radionuclides following neutron 
activation of the glass. The radionuclides could simultaneously irradiate the target tissue and the 
differences in half-lives and emission energies could be utilised to optimise the radiation delivered 
to the tumour, dependent on it its size and location [141].  
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Table 3 Materials used to fabricate microspheres and investigated for in situ delivery 
of radiation therapy. 
Material Particle 
size (µm) 
Manufacturing 
Method 
Application Advantage Disadvantage Reference 
Yttrium 
alumina 
silicate MS 
20-50  Flame 
spheroidisation 
Radiotherapy 
application 
Safe, highly 
durable 
Non-degradable [121] 
[120] 
[142] 
Yttrium 
silicate MS 
20-50  Silicon oil 
method 
Radiotherapy Low leaching 
ability 
- [143] 
Yttrium 
phosphate 
ceramic MS 
20-30  W/O emulsion Deep-seated 
cancer 
High 
phosphorous 
content 
Low chemical 
durability 
[144] 
Yttrium oxide 
MS 
20-30 Enzymatic 
reaction 
Deep seated 
cancer 
Low density, high 
chemical 
durability 
Microspheres 
may accumulate 
in the blood 
vessels of 
patients 
[145] 
Phosphate 
glass MS 
20-30 Flame 
spheroidisation 
Radiotherapy Easy to prepare, 
controllable 
chemical 
durability 
Loss of 
phosphorous 
content during 
processing 
[128] 
Holmium 
doped 
phosphate 
based glass 
MS 
45-63  Flame 
spheroidisation 
and 
spheroidisation 
by gravitational 
falling in a 
tubular furnace 
Radiotherapy Low density, high 
amount of 
Holmium, gamma 
emitter allowing 
for SPECT 
detection  
Partial 
crystallisation 
may be occurred 
during 
spheroidisation 
[132] 
Alumina 
borate glass 
doped with 
rhenium MS 
25-32  Flame 
spheroidisation 
using 
propane/air 
flame 
In vivo 
radioembolis
ation therapy 
Neutron 
activated within 
10 hours, 
Imaging of 
biodistribution 
possible, safe 
radiation release 
Non degradable [129] 
Alumina 
silicate glass 
MS doped 
with yttrium 
and lutetium  
20-40  Sol-gel method Treatment of 
hepatic 
tumors with 
SPECT 
imaging 
capabilities 
Bio-distribution is 
possible via 
SPECT imaging 
Inhomogeneous 
microspheres 
[146] 
*MS= Microspheres. 
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6. Bone Cements and Radiotherapy for the Treatment of Spinal Metastases  
Vertebral metastases are a common manifestation of many cancers and the proximity of 
vertebral metastases to the spinal cord can result in debilitating pain as well as severe neurological 
complications in the event of vertebral collapse. In cases of metastatic spinal cord compressions, 
the treatment regimens must address the tumour itself as well as restoring the structural integrity 
of the vertebrae [147]. Vertebroplasty or kyphoplasty is performed in such instances and are 
surgical procedures involving the injection of a bone cement into the vertebral body to restore 
strength. This is conventionally followed by multiple session of external beam radiation therapy to 
control and arrest tumour growth as well as providing pain relief. Despite advances in conformal 
EBRT, concerns about the safety of this technique arise due to potential irradiation of adjacent 
radiosensitive spinal cord tissue [148]. An alternative approach that has been considered is the 
incorporation of radionuclides into the bone cement.  
Polymethylmethacrylate (PMMA) is the most commonly used material to form bone cement 
due to its good mechanical properties and its ability to be administered via a minimally invasive 
percutaneous procedure [149]. Donanzam et al. investigated combining PMMA with calcium 
phosphate ceramics that contained β-emitting radionuclides integrated within their structure as 
novel biomaterial to treat spinal metastases [150]. Calcium phosphate based biomaterials have 
been extensively studied for bone repair and regeneration due to their bioactivity, 
osteoconductive properties and similarity of their chemical composition to that of bone [151]. 
They offer flexibility in their composition and synthesis by techniques such as sol-gel and melt 
quenching. In their work, Donanzam et al. formed composite PMMA with multiphasic calcium 
phosphates that incorporated either holmium or samarium. Upon neutron activation the 
radioisotopes 166Ho and 153Sm were produced with activates calculated to be 32.5 and 14.5 
MBq/mg, which was considered to be clinically suitable for site specific radiotherapy. PMMA 
injection itself was believed to have antitumour effects which were driven by the exothermic 
reaction of its polymerisation in vivo. The hyperthermia induced death of the tumour cells and its 
neovascular network can arrest tumour growth in addition to the bone cement inhibiting the 
region in which the tumour can grow into. The synergistic effect of PMMA cement and 
radiotherapy is anticipated to lead to a more efficacious treatment [152]. Other radionuclides such 
as 32P, 188Re and 153Sa have also been investigated as radionuclides that could augment the 
symptomatic relief provided by vertebroplasty to patients with vertebral metastases [153, 154]. 
Although preliminary studies, biomaterials such as these provide a novel approach to integrate 
radiotherapy with vertebroplasty to form a convenient, single treatment procedure with enhanced 
clinical benefits over a sustained period [155].  
The incorporation of radionuclides onto or within the structure of various biomaterials can 
facilitate the targeted and sustained delivery of radiotherapy to cancerous tissue. Each 
radionuclide has their own characteristic energy spectrum and particle emission [153]. The 
different particle energies and half-lives can be utilised to increase the spatial-temporal 
localisation of radiation and be used to customise the length and intensity of the absorbed 
radiation dose received (see Table 4). Sophisticated software and modelling programs can be used 
to predict the dose distribution from the radionuclide source, or combination of different sources, 
and can evaluate the suitability of potential new treatment methods. 
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Table 4 Characteristics of β-emitting radionuclides that have been investigated for the 
in situ delivery of radiation therapy. Mev, mega-electronvolts; keV, kilo-electronvolts. 
Radionuclide Half-life 
(days) 
Maximum β 
particle energy 
(MeV) 
Maximum γ 
particle energy 
(keV) 
Maximum tissue 
penetration range 
(mm) 
Reference 
32P 14.3 1.71 / 8.7 [156] 
47Sc 3.4 0.600 159.4 3 [157] 
67Cu 2.6 0.575 184.6 2.2 [158] 
89Sr 50.5 1.492 / 8 [20] 
90Y 2.7 2.284 / 11 [112] 
131I 8 0.81  0.364 2.4 [26] 
153Sm 1.95 0.808 103 3 [154] 
161Tb 6.9 0.593 74.6 3 [159] 
166Ho 1.1 1.84 81 8.7 [132] 
177Lu 6.7 0.497 208  2.2 [27] 
186Re 3.8 1.07 137 4.5 [140] 
188Re 0.7 2.118 155 11 [51] 
7. Utilising Biomaterials for Targeted Drug Delivery during Radiotherapy  
The synergistic effect of chemotherapy and radiotherapy has the potential to enhance cancer 
treatment efficacy and a consequential reduction in the treatment time for patients. 
Chemotherapy is commonly employed as an adjuvant therapy prior and following radiotherapy to 
enhance its tumorcidal ability. Chemotherapy is predominantly administered systemically and is 
often non-selective, which can cause radiosensitivity of healthy tissue and therefore limits drug 
dosage and potential efficacy [160]. Strategies involving the use of biomaterials have been 
adopted capable of delivering chemotherapeutics in a site-specific manner to increase the efficacy 
of radiotherapy. 
Gliomas are the most prevalent form of brain tumour and require intratumoral delivery of 
chemotherapeutics during radiotherapy in order to reduce toxicity to surrounding critical tissue 
and to circumvent the blood brain barrier [161]. Liang et al. investigated the use of oxidised 
hyaluronic acid/adipic acid dihydrazide (oxi-HA/ADH) hydrogel as a biocompatible, thermogelling 
material to be used for the targeted, sustained delivery of the antineoplastic agent carboplatin 
[162]. The oxi-HA/ADH hydrogel was injected intratumorally in a cool liquid form, where it then 
configured into a gel-like matrix at body temperature within 1 to 8 minutes depending on 
operational temperatures. The hydrophilic carboplatin was administered with the hydrogel and 
retained in the matrix structure following crosslinking. The naturally occurring hyaluronidase 
enzymes can gradually degrade the hydrogel facilitating the sustained release of carboplatin. 
Carboplatin forms inter-strand and intra-strand cross links with purine bases of DNA causing 
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inhibition of DNA repair and therefore augmented radiation-induced DNA damage and subsequent 
apoptosis [163].  
Biomaterials that are responsive to radiation are being developed for novel approaches such as 
drug delivery vehicles at sites being irradiated. Fan et al. synthesised a gamma radiation-
responsive amphiphilic polymer with tellurium-containing side-chains (PEG-b-PAA-g-Te) for 
targeted drug delivery [164]. Tellurium-containing compounds have been explored as anticancer 
agents since they are capable of increasing intracellular oxidative stress, generating ROS and 
converting less-reactive-ROS into higher reactive species [165]. The PEG-b-PAA-g-Te polymer 
coordinated with anticancer agent cisplatin and was self-assembled in an aqueous solution. This 
resulted in cisplatin being retained in the hydrophobic core of the polymer nanoparticles. The 
coordination of the two anticancer agents provisionally reduced their cytotoxic effects and 
thereby reduced to an extent some of the adverse off-target effects associated when 
administered. A low dosage of gamma radiation caused the tellurium side-chain of the polymer to 
become oxidised. This oxidation increased the hydrophilicity of the polymer and caused the 
nanoparticles to disassemble. The oxidation and subsequent disassembly caused weakening of the 
coordination between cisplatin and the tellurium, resulting in both compounds being exposed and 
able to elicit their cytotoxic tumour effects [164]. Cisplatin inhibits DNA replication and repair 
during the S phase of cell cycle and can therefore enhance radiation-induced apoptosis of 
irradiated cancer cells [166]. The material is responsive to the radiation and can enhance the 
delivery of anticancer agents in a site-specific manner whilst sparing the tissue that is not-being 
irradiated to reduce off target effects. 
It has been well established that elevated levels of ROS are produced within cells following 
targeted radiation of cancerous tissue which is succeeded by intracellular reoxygenation post 
irradiation [35]. Utilising the high oxidative reactivity of ROS has been explored as an internal 
stimulus to selectively enhance drug delivery within irradiated tumours. Liu et al. developed ROS-
responsive poly(tehiodiethylene adipate) (PSDEA) and PEG-PSDEA-PEG polymers as a drug delivery 
system to synergistically enhance the efficacy of radiotherapy by local ROS-activated 
chemotherapy [167]. The PSDEA and PEG-PSDEA-PEG polymers were synthesised into drug loaded 
nanoparticles via a nanoprecipitation method and self-assembly. This resulted in the 
encapsulation of hydrophobic anticancer camptothecin analogue, SN38, within the polymer 
nanoparticles, by hydrophobic association, thereby enhancing the stability of the drug under 
physiological conditions. The hydrophobic sulphide residues of the polymer chains were found to 
undergo ROS-mediated oxidation into hydrophilic sulfoxide groups. As a result, polymer 
nanoparticles experienced structural changes such as swelling and partial dissociation which 
caused significant unloading of SN38 from the nanoparticles (see Figure 8). In vivo studies showed 
that tumour growth was significantly inhibited in mice that received dual treatment modality of 
local X-ray irradiation in conjunction with intratumoral injection of SN38-loaded polymer 
nanoparticles when compared to either single treatment modality. This nanoparticle biomaterial 
system improves selective drug delivery by utilising nanoparticles preferential accumulation within 
tumours and alleviated issues associated with hydrophobic drug delivery [168]. Materials that 
respond to the local changes that radiotherapy, delivered internally or external, can induce to 
liberate drugs from their structure in a controllable manner can increase the spatio-temporal 
delivery of chemotherapeutics that have the ability to significantly improve the efficacy of 
radiotherapy.  
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Figure 8 Schematic of the fabrication and mechanism by which ROS-responsive 
polymer nanoparticles can selectively release SN38 to synergistically enhance the 
efficacy of radiotherapy by local ROS-activated chemotherapy. Reproduced with 
permission from Copyright (2018) American Chemical Society [167].  
Biomaterials can be used to augment current methods of radiation delivery and in many 
instances their use can be integrated in current treatment procedures. These biomaterial devices 
can be placed in close proximity to cancerous regions allowing the in situ delivery of radiation in a 
targeted manner. Novel biomaterials continue to be developed that can enhance the synergistic 
effect of other treatment modalities, such as chemotherapy and immunotherapy, and that can 
respond to various stimuli to deliver therapeutic payloads to target tissue to improve treatment 
efficacy. 
8. Conclusions 
The majority of improvements in EBRT have been as a result of technological advances in 
imaging modalities used to plan procedures and equipment to accurately deliver the radiation 
dose. Despite the ability to control their intensity and to modulate the shape of several beams 
from multiple angles, externally administered radiation has to pass through tissue to reach its 
target which can limit application and utility for treatment of certain cancers. Internal radiation is 
advantageous in that much larger localised doses of therapeutic radiation can be delivered using 
shorter range radionuclides. Polymer based materials, such as PEG hydrogels, have been explored 
to displace adjacent healthy tissue to prevent radiation-induced toxicities and as drug delivery 
vehicles to locally administer chemotherapeutics to enhance radiotherapy. Glass-based 
biomaterials doped with radionuclides, such as 90Y and 166Ho, have been developed and processed 
into microspheres capable of selectively irradiating tumours following their implantation into the 
body. These alpha, beta or gamma producing radionuclides have been chemically incorporated 
into glass compositions and the ability to process glass into desired sizes and practical 
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morphologies facilitates their transport and delivery to specific target locations to provide in situ 
radiotherapy. Theranostic materials capable of providing diagnostic information whilst 
simultaneously delivering a therapeutic effect to enhance radiotherapy continue to be developed. 
Enhancing conventionally employed biomaterials, such as PMMA bone cements, to also deliver 
radiation has the potential to improve cancer treatment efficacy. New biomaterials continue to be 
developed to enhance the synergistic effect of other treatment modalities, such as chemotherapy 
and immunotherapy, by responding to radiation-induced stimuli and providing localised delivery 
of therapeutic payloads. 
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